Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | DDX3X | O00571 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060979 | 0.87 | NOTUM (0.79) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL13526965 | 0.82 | NOTUM (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL21792141 | 0.81 | NOTUM (1.00) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL21157740 | 0.81 | NOTUM (0.57) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL27984098 | 0.75 | NOTUM (0.69) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL19211467 | 0.74 | P2RX7 (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL21156444 | 0.73 | CYP19A1 (0.74) | NOTUM | |
| SCHEMBL19211396 | 0.73 | NOTUM (1.00) | NOTUMP2RX7KDM4EMAPTL3MBTL1 | |
| SCHEMBL21156929 | 0.72 | MIF (0.50) | NOTUMP2RX7KDM4EMAPTCA1 | |
| SCHEMBL19211427 | 0.71 | NOTUM (0.67) | NOTUMP2RX7KDM4EMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | NOTUM 3719/4885P2RX7 961/4885KDM4E 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.